(NASDAQ: OCGN) Ocugen's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.62%.
Ocugen's earnings in 2026 is -$67,846,000.On average, 9 Wall Street analysts forecast OCGN's earnings for 2026 to be -$74,531,055, with the lowest OCGN earnings forecast at -$83,548,231, and the highest OCGN earnings forecast at -$65,415,511. On average, 7 Wall Street analysts forecast OCGN's earnings for 2027 to be -$66,235,254, with the lowest OCGN earnings forecast at -$118,895,560, and the highest OCGN earnings forecast at $41,315,059.
In 2028, OCGN is forecast to generate $5,016,829 in earnings, with the lowest earnings forecast at -$128,535,740 and the highest earnings forecast at $285,762,493.